RecruitingEarly Phase 1NCT06775912

Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

Sponsor

Nanjing Bioheng Biotech Co., Ltd.

Enrollment

18 participants

Start Date

Jan 3, 2025

Study Type

INTERVENTIONAL

Conditions

SLE Systemic Sclerosis NMOSD MS IIM ANCA Associated Vasculitis (AAV)MG

Summary

This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with active SLE, SSc, AAV, IIM, NMOSD, MS, MG

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called RD06-05 CART Cell Injection for people with anca associated vasculitis (aav), iim, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.